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Book Reviews
Prediction of Response in Cancer
Therapy. Edit. THOMAS C. HALL. U.S.
Department of Health Education and
Welfare Public Health Service, National
Institutes of Health, National Cancer
Institute, Bethesda, Maryland 20014. 298
pages. Price $4.50.
This is National Cancer Institute Mono-
graph No. 34 and it contains the proceedings
of a symposium held at Cascades Conference
Centre, Virginia, in February 1970.
There are 9 panels each containing 2 to 7
papers and an account of the ensuing dis-
cussion. The subjects of the panels are Cell
Kinetics and Therapeutic Response, Hor-
monal Influences, Immunologic Factors,
Genetic Factors, Studies in Leukaemia,
Studies with Solid Tumours, In vivo Histo-
logic Studies, In vivo Predictive Tests and
Clinicoepidemiologic Factors. There are 35
papers by authors who are distinguished in
their fields and the general presentation of
the material is excellent. The greater part
ofthe work presented is from the laboratory,
but most of it has immediate clinical rele-
vance. There are papers referring to radia-
tion treatment and to surgery (especially
" endocrine surgery ") but most of the
monograph is devoted to the drug treatment
of malignant disease with an emphasis on
biochemical aspects and tests. The poten-
tial value of methods of prediction both in
the selection of the most effective treatment
and in the avoidance of ineffective treatment
with its unnecessary drug toxicity, or surgical
hazards, is self evident.
Individual mention cannot be made of all
papers so 4 which share a common theme are
selected. Hilf draws attention to some
similarities between rodent and human
breast cancer which suggest that the former
is a reasonable " model " to use. He then
goes on to demonstrate that glucose-6
phosphate dehydrogenase levels may be high
in tumours which are unresponsive to oestro-
gen, and low in responsive tumours and that
the level rises during treatment. Another
enzyme, a-glycerophosphate dehydrogenase
is found at high levels in normal breast tissue
and in responsive tumours but at low levels
in unresponsive tumours. Jensen and col-
leagues describe the two-stage binding of
oestradiol to protein and its incorporation
into the nucleus, and follow this with a
tentative demonstration that if a breast
tumour lacks oestrogen receptor substance
then it is unlikely to respond to endocrine
therapy. Braunsberg and colleagues using
tritiated steroid show that testosterone is not
concentrated in breast cancer but that
oestrogen is concentrated in some, though
not all. Dao and Libby describe bio-
chemical work on the conjugation of oestra-
diol and dehydroepiandrosterone (D.H.E.A.)
by mammary cancer tissue. They suggest
that with a D.H.E.A. to oestradiol uptake of
greater than unity fewer patients have
metastases and those who do are more likely
to respond to adrenalectomy, but with a
ratio of less than unity metastases are more
common and few regress after adrenalectomy.
The inactive tumours also fail to respond to
adrenalectomy. These 4 papers all seem to
point in the same direction and suggest that
one should be able to select the hormone-
responsive breast cancers on a less empirical
basis than previously.
Each panel is concluded by valuable dis-
cussion which should not be overlooked.
One of the few defects in the presentation is
that many of the papers do not contain
summaries.
This monograph contains many examples
of fruitful cooperation between laboratory
and clinical workers and is strongly recom-
mended to both.
I. D. H. TODD
The Design of Clinical Trials in Cancer
Therapy. Edit. M. STAQUET. Brussels:
Editions Scientifique Europeennes. (F.B.
690.)
This is a report of the proceedings of a
course in clinical pharmacology held at the
Institute Jules Bordet, Brussels in May 1972,
under the auspices of the EORTC.
There are 15 authors from Europe and the
United States all with established reputations
inthis field. Two ofthe papers are in French,
the remainder are in English. The book is
divided into 5 chapters. The first deals with
animal screening and toxicity-it contains 4
papers by Goldin and one by Eckhardt.
The second is about the experimental bases
of the use of chemotherapy in man and is424 BOOKS
devoted primarily to the influence of recent
work on cell kinetics-the authors are van
Putten, Stryckmans, Cooper, Peperzeel and
Israel. The third chapter is concerned with
the evaluation of anticancer drugs and is
written by Amiel, Smets and Carter. Chapter
4 is on clinical pharmacology and toxicity,
with contributions from Harrap, Carter,
Kenis, Klastersky and Staquet. The final
chapter is a brief account of the aims,
structure, and activities of the EORTC.
As can be deduced from the chapter
headings much relevant material is presented
but this book should not be regarded as a
comprehensive text on its subject as, for
example, statistical aspects are touched upon
but briefly and ethics not at all. However,
there is an abundance of basic facts and
also some more speculative writing such as
Carter's " Some Thoughts on Combination
Chemotherapy of Breast Cancer".
The National Cancer Institute, Bethesda,
as represented by Goldin and Carter, has a
major influence on the book and they give a
very fair reflection of the importance of this
institute in the field. It is clear also that
the ground work put into the EORTC is
now beginning to bear fruit.
The standard of presentation is high and
the book should appeal primarily to clinicians
with a major interest in the drug treatment
of malignancy, but must also be of con-
siderable interest to associated laboratory
workers.
It is a triumph for the publishers to have
the book in print within two months of the
course.
I. D. H. TODD
Meeting Announcement
SECOND INTERNATIONAL SYMPOSIUM
ON CANCER DETECTION AND
PREVENTION
Bologna (Italy), April 9-12, 1973
The Second International Symposium on
Cancer Detection and Prevention, promoted
by the International Study Group on Detec-
tion and Prevention of Cancer, unider the
auspices of the International Union against
Cancer (UICC) and of the International
Agency for Research on Cancer (IARC) of
the World Health Organisation, and orga-
nized by the Instituto di Oncologia " F.
Addarii " and Bologna Cancer Centre, will be
held in Bologna from April 9 to 12, 1973.
The objectives of the Symposium are the
discussion and the evaluation of the most
recent knowledge and results in the field of
cancer prevention and detection.
The programme includes:
Cancer prevention by environmental con-
trol.
Occupational carcinogenesis.
Host factors in oncogenesis.
Recent advances and perspectives of auto-
mation in cytology.
Aspects of experimental carcinogenesis
related to cancer prevention.
Evaluation of cancer control measures.
Carcinogenic hazards from drugs.
The possible importance of nitrosamines as
carcinogens in humans.
There will also be special panels on the
scientific basis and possibilities of detection
and prevention of:
Cancer of the breast, lung, alimentary
tract, urinary tract and cervix, public
health aspects in Cancer Control, and
recent advances on tumours with parti-
cular racial and geographic distribution
(oral cancer, Burkitt's lymphoma, naso-
pharyngeal cancer, liver cancer).
Workshops for registered participants are
planned during the 2 days following the
Symposium (April 13 and 14) on: epidemio-
logical techniques, cell pathology, thermo-
graphy, testing ofenvironmental carcinogens,
cytogenetics, needle aspiration cytology,
gastric cytology.
Secretariat:
2nd International Symposium on Cancer
Detection and Prevention,
Istituto di Oncologia " F. Addarii"
Viale Ercolani 4/2-40138 Bologna, Italy.
Phone 051-390417,
Cable Depea-Bologna.